Novel vancomycin free base-Sterosomes for combating diseases caused by Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus infections (S. Aureus and MRSA)

被引:0
|
作者
Nwabuife, Joshua C. [1 ]
Hassan, Daniel [1 ]
Pant, Amit Madhaorao [1 ]
Devnarain, Nikita [1 ]
Gafar, Mohammed Ali [1 ]
Osman, Nawras [1 ]
Rambharose, Sanjeev [2 ]
Govender, Thirumala [1 ]
机构
[1] Univ KwaZulu Natal, Coll Hlth Sci, Discipline Pharmaceut Sci, ZA-4000 Durban, South Africa
[2] Stellenbosch Univ, Fac Sci, Dept Physiol Sci, Private Bag X1 Matieland, ZA-7602 Stellenbosch, South Africa
基金
新加坡国家研究基金会; 英国医学研究理事会;
关键词
Sterosomes; Novel delivery systems; Antimicrobial resistance; DRUG-DELIVERY SYSTEMS; IN-VITRO; NANOPARTICLES; ACID; NANOTECHNOLOGY; NANOSYSTEM; NANOSPHERES; PATHOGENS; EFFICACY; POLYMER;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A clarion call to save antimicrobials is the need for the evolution of novel delivery systems to combat resistance posed by Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus (S. aureus and MRSA) to conventional forms. Herein, we present a novel vancomycin free base - sterosomes (VCM-FB - Sterosomes) for vancomycin free base (VCM-FB) delivery against S. aureus and MRSA. VCM-FB - Sterosomes were prepared using the thin-film hydration method and were characterised physiochemically, in silico, in vitro and in vivo. In vitro cytotoxicity on MCF-7 and HEK-293 cell lines were evaluated, with results revealing cell viability above 70% after exposure to VCM-FB - Sterosomes, indicating biosafety. VCM-FB - Sterosomes had a hydrodynamic diameter, polydispersity index and surface-charge of 114.14 +/- 0.59 nm, 0.210 +/- 0.02 and +36.3 +/- 5.42 mV, respectively, with entrapment efficiency, drug loading and VCM-FB release after 48 h of 79.61 +/- 0.59%, 90.91% w/w and 54.95 +/- 9.75% respectively. In silico studies showed a self-assembly in five nano seconds, which was stable thereafter. VCM-FB - Sterosomes were seen to be stable over 90 days and were also non-hemolytic. VCMFB - Sterosomes showed a 2-fold superior minimum inhibition efficiency (MIC) against S. aureus and MRSA, relative to bare VCM-FB, with MICs of 1.95 mu g/mL and 0.98 mu g/mL for VCM-FB and VCM-FB - Sterosomes (S. aureus), and 7.81 mu g/mL and 3.91 mu g/mL for VCM-FB and VCM-FB - Sterosomes (MRSA), respectively. A faster bacterial killing time was also recorded for VCM-FB - Sterosomes compared to bare VCM-FB. Greater MRSA membrane damage was indicated by an increase and decrease in electrical conductivity, and protein/DNA concentration, respectively. VCM-FB - Sterosomes showed superior MRSA biofilm reduction (27.22%) compared to VCM-FB (2.53%). In vivo BALB/c mice-infected skin model showed that VCM-FB - Sterosomes had significant MRSA eradication (27-fold) compared to bare VCM-FB (4-fold). These results amplify the superiority of VCM-FB - Sterosomes for S. aureus and MRSA infection treatment compared to conventional forms.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Novel vancomycin free base - Sterosomes for combating diseases caused by Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus infections (S. Aureus and MRSA)
    Nwabuife, Joshua C.
    Hassan, Daniel
    Pant, Amit Madhaorao
    Devnarain, Nikita
    Gafar, Mohammed Ali
    Osman, Nawras
    Rambharose, Sanjeev
    Govender, Thirumala
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2023, 79
  • [2] Delivery of novel vancomycin nanoplexes for combating methicillin resistant Staphylococcus aureus (MRSA) infections
    Hassan, Daniel
    Omolo, Calvin A.
    Gannimani, Ramesh
    Waddad, Ayman Y.
    Mocktar, Chunderika
    Rambharose, Sanjeev
    Agrawal, Nikhil
    Govender, Thirumala
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2019, 558 : 143 - 156
  • [3] Staphylococcus aureus: Methicillin-Susceptible S. aureus to Methicillin-Resistant S. aureus and Vancomycin-Resistant S. aureus
    Rehm, Susan J.
    Tice, Alan
    CLINICAL INFECTIOUS DISEASES, 2010, 51 : S176 - S182
  • [4] Approaches to combating methicillin-resistant Staphylococcus aureus (MRSA) biofilm infections
    Le, Katherine Y.
    Otto, Michael
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (01) : 1 - 3
  • [5] Affinity Apheresis for Treatment of Bacteremia Caused by Staphylococcus aureus and/or Methicillin-Resistant S. aureus (MRSA)
    Mattsby-Baltzer, Inger
    Bergstrom, Tomas
    McCrea, Keith
    Ward, Robert
    Adolfsson, Lars
    Larm, Olle
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2011, 21 (06) : 659 - 664
  • [6] Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) at ambient freshwater beaches
    Fogarty, Lisa R.
    Haack, Sheridan K.
    Johnson, Heather E.
    Brennan, Angela K.
    Isaacs, Natasha M.
    Spencer, Chelsea
    JOURNAL OF WATER AND HEALTH, 2015, 13 (03) : 680 - 692
  • [7] Reducing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
    Griffin, Frances A.
    JOINT COMMISSION JOURNAL ON QUALITY AND PATIENT SAFETY, 2007, 33 (12): : 726 - 731
  • [8] Methicillin-Resistant Staphylococcus aureus (MRSA)
    Randolph, Susan A.
    WORKPLACE HEALTH & SAFETY, 2012, 60 (03) : 136 - 136
  • [9] Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Children: a Reappraisal of Vancomycin
    Sharma, Roopali
    Hammerschlag, Margaret R.
    CURRENT INFECTIOUS DISEASE REPORTS, 2019, 21 (10)
  • [10] Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Children: a Reappraisal of Vancomycin
    Roopali Sharma
    Margaret R. Hammerschlag
    Current Infectious Disease Reports, 2019, 21